Loading...
OTCMAXIM
Market cap573kUSD
Dec 27, Last price  
0.00USD
1D
5.56%
1Q
-69.84%
Jan 2017
-99.98%
IPO
-99.24%
Name

Axim Biotechnologies Inc

Chart & Performance

D1W1MN
OTCM:AXIM chart
P/E
—
P/S
14.52
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
31.78%
Rev. gr., 5y
-27.38%
Revenues
40k
+345.27%
10,00043,33321,667049,13947,05947,573195,614799,483060,4608,87539,518
Net income
-8m
L+35.30%
-2,794-14,904-89,219-582,947-10,092,766-5,809,906-4,168,203-6,754,646-6,771,465-6,730,693-16,518,130-5,956,966-8,059,682
CFO
-1m
L-49.59%
4,03821,105-33,018-338,999-1,539,178-1,294,141-3,081,956-4,845,269-5,020,142-3,215,699-2,486,765-2,044,326-1,030,500
Earnings
May 19, 2025

Profile

AXIM Biotechnologies, Inc. develops and sells diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and oncology. The company is developing rapid diagnostic tests, which measure the levels of functional neutralizing antibodies that prevent SARS-CoV-2 from attaching to human cells; serological diagnostic test, which detect neutralizing antibodies that measure adaptive immune response to the SARS-CoV-2 virus; and tests for management of COVID-19 Patients to detect biomarkers related to inflammation. It is also developing rapid quantitative tear tests for Matrix metalloproteinase-9, an inflammatory biomarker for dry eye disease; SBI-183, an anti-metastatic compound suppressing tumor cell growth and blocking metastasis; and SPX-1009, an anti-metastatic treatment to measure levels of quiescin sulfhydryl oxidase I. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California.
URL
https://aximbiotech.com/
IPO date
Apr 09, 2013
Employees
6
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
40
345.27%
9
-85.32%
60
 
Cost of revenue
125
580
285
Unusual Expense (Income)
NOPBT
(86)
(571)
(224)
NOPBT Margin
Operating Taxes
(286)
494
Tax Rate
NOPAT
(86)
(285)
(718)
Net income
(8,060)
35.30%
(5,957)
-63.94%
(16,518)
145.41%
Dividends
Dividend yield
Proceeds from repurchase of equity
491
2,197
25,001,636
BB yield
-11.36%
-47.94%
-43,895.80%
Debt
Debt current
190
20
1,638
Long-term debt
5,795
5,665
5,158
Deferred revenue
Other long-term liabilities
236
Net debt
5,829
5,591
6,239
Cash flow
Cash from operating activities
(1,030)
(2,044)
(2,487)
CAPEX
(9)
(50)
Cash from investing activities
(9)
(50)
Cash from financing activities
1,140
1,647
2,533
FCF
1,987
2,637
(593)
Balance
Cash
156
47
453
Long term investments
46
104
Excess cash
154
93
554
Stockholders' equity
(72,160)
(63,971)
(53,338)
Invested Capital
70,493
64,810
57,719
ROIC
ROCE
5.16%
EV
Common stock shares outstanding
227,691
165,468
131,540
Price
0.02
-31.41%
0.03
-93.60%
0.43
0.70%
Market cap
4,326
-5.61%
4,583
-91.95%
56,957
19.99%
EV
10,155
10,175
63,196
EBITDA
341
(145)
1,891
EV/EBITDA
29.78
33.41
Interest
1,205
1,876
486
Interest/NOPBT